GlassScriptPhysician profile
Brooke N Shadel
NPI 1134327018
$1,772.32
in general payments reported to CMS, 2019-2025
13 companies · $524 in 2025
The $524 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $173 · 2020: $47.06 · 2021: $107 · 2022: $41.11 · 2023: $425 · 2024: $454 · 2025: $524.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $336.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,067.36 |
| Education | $336.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $645.43 | 2021-2025 | |
| Janssen Biotech, INC. | $353.81 | 2021-2025 | Tremfya |
| Pfizer INC. | $165.83 | 2019-2025 | |
| Abbvie INC. | $157.64 | 2019-2023 | Skyrizi |
| Botanix Sb INC | $137.81 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $123.96 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $61.87 | 2022-2025 | Sotyktu |
| Verrica Pharmaceuticals INC. | $35.84 | 2024 | Ycanth |
| Biofrontera INC. | $24.17 | 2025 | Rhodoled Xl, Ameluz, Bf-Rhodoled |
| Almirall LLC | $22.87 | 2025 | Seysara, Klisyri |
| Amgen INC. | $15.04 | 2019 | |
| Strata Skin Sciences, INC. | $14.08 | 2025 | Xtrac |
| Arcutis Biotherapeutics, INC. | $13.97 | 2024 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Shadel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.